Xencor Inc (XNCR):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7614)
◆英語タイトル:Xencor Inc (XNCR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7614
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:63
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. The company provides pipeline products under preclinical development such as XmAb14045, for the treatment of acute myeloid leukemia; XmAb 5871, for treating IgG4-related disease, and also for the treatment of systemic lupus erythematosus; XmAb 7195. It offers treatment services which are being developed for asthma and allergic diseases; and XmAb13676, used in the treatment of B-cell malignancies. Xencor utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates. The company’s works in partnership with pharmaceutical and biotechnology companies such as Morphosys, Janssen, Amgen, Novartis and others for their research and development activities. Xencor is headquartered in Monrovia, California, the US.

Xencor Inc (XNCR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xencor Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Xencor Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xencor Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Xencor Raises US$7.6 Million In Venture Financing 11
Partnerships 12
Applied BioMath Enters into Partnership with Xencor 12
Selexis Enters into Agreement with Xencor 13
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 14
Licensing Agreements 15
Xencor Enters into Licensing Agreement with Selexis 15
INmune Bio Enters into Licensing Agreement with Xencor 16
Novartis Enters into Licensing Agreement with Xencor 17
Xencor Enters into Licensing Agreement with Selexis for XmAb-13676 18
Xencor Enters into Licensing Agreement with Receptor Logic 19
Xencor Enters Licensing Agreement with Catalent Pharma Solutions 20
Xencor Enters into Licensing Agreement with Selexis 21
Amgen Enters into Licensing Agreement with Xencor 22
Xencor Enters Into Licensing Agreement With Merck 24
CSL Enters into Licensing Agreement with Xencor 25
Xencor Enters into Licensing Agreement with Alexion Pharma 26
sAber Bioscience Enters Into Licensing Agreement With Xencor For XmAb Technology 28
FPRT Bio Enters into Licensing Agreement with Xencor for XPro1595 29
Equity Offering 30
Xencor Prices Public Offering of Shares for USD226.3 Million 30
Xencor Raises USD126.5 Million in Public Offering of Shares 32
Xencor Raises USD123 Million in Public Offering of Shares 34
Xencor Completes IPO For US$80.5 Million 36
Xencor Inc – Key Competitors 38
Xencor Inc – Key Employees 39
Xencor Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Strategy And Business Planning 41
Jan 05, 2018: Xencor Announces 2018 Priorities and Expected Milestones 41
Financial Announcements 43
Aug 06, 2018: Xencor announces second quarter 2018 financial results 43
May 07, 2018: Xencor Announces First Quarter 2018 Financial Results 45
Feb 27, 2018: Xencor Reports Fourth Quarter and Full Year 2017 Financial Results 47
Nov 07, 2017: Xencor Reports Third Quarter 2017 Financial Results 50
Aug 07, 2017: Xencor Reports Second Quarter 2017 Financial Results 53
May 09, 2017: Xencor Reports First Quarter 2017 Financial Results 55
Feb 28, 2017: Xencor Reports Fourth Quarter and Full Year 2016 Financial Results 57
Corporate Communications 60
Dec 19, 2017: Xencor Appoints Richard Ranieri to Board of Directors 60
Mar 06, 2017: Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders 61
Clinical Trials 62
Mar 01, 2017: Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research 2017 Annual Meeting 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
Xencor Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xencor Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xencor Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Xencor Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xencor Raises US$7.6 Million In Venture Financing 11
Applied BioMath Enters into Partnership with Xencor 12
Selexis Enters into Agreement with Xencor 13
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 14
Xencor Enters into Licensing Agreement with Selexis 15
INmune Bio Enters into Licensing Agreement with Xencor 16
Novartis Enters into Licensing Agreement with Xencor 17
Xencor Enters into Licensing Agreement with Selexis for XmAb-13676 18
Xencor Enters into Licensing Agreement with Receptor Logic 19
Xencor Enters Licensing Agreement with Catalent Pharma Solutions 20
Xencor Enters into Licensing Agreement with Selexis 21
Amgen Enters into Licensing Agreement with Xencor 22
Xencor Enters Into Licensing Agreement With Merck 24
CSL Enters into Licensing Agreement with Xencor 25
Xencor Enters into Licensing Agreement with Alexion Pharma 26
sAber Bioscience Enters Into Licensing Agreement With Xencor For XmAb Technology 28
FPRT Bio Enters into Licensing Agreement with Xencor for XPro1595 29
Xencor Prices Public Offering of Shares for USD226.3 Million 30
Xencor Raises USD126.5 Million in Public Offering of Shares 32
Xencor Raises USD123 Million in Public Offering of Shares 34
Xencor Completes IPO For US$80.5 Million 36
Xencor Inc, Key Competitors 38
Xencor Inc, Key Employees 39
Xencor Inc, Other Locations 40

List of Figures
Xencor Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xencor Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xencor Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Xencor Inc (XNCR):製薬・医療:M&Aディール及び事業提携情報(Xencor Inc (XNCR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆